Skip to main content

Table 1 Clinical and pathological characteristics and univariate analysis for DFS

From: Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer

Factors Number (%) Median DFS (months) P value
Sex male 111 (73.5) 33.99 0.036*
  female 40 (26.5) 21.13  
Age <55 years 74 (49.0) 21.45 0.330
  ≥55 years 77(51.0) 31.97  
Smoking status no 65 (43.0) 22.24 0.305
  yes 86 (57.0) 32.99  
Stage I 54 (35.8) NR# 0.001*
  II 47 (31.1) 33.64  
  III 50 (33.1) 15.18  
T stage T1 38 (25.2) NR# 0.03
  T2 99 (65.5) 18.76  
  T3-4 14 (9.3) 38.16  
N stage N0 62 (41.1) NR# <0.001*
  N1 50 (33.1) 33.64  
  N2 39 (25.8) 13.37  
Histology Adenocarcinoma 59 (39.1) 17.41 0.004*
  Non- adenocarcinoma 92 (60.9) 48.16  
Surgery method Wedge resection 5 (3.3) 17.41 0.958
  Lobectomy 123 (81.5) 24.41  
  Pneumonectomy 23 (15.2) 31.15  
Chemotherapy regimens Docetaxel-containing 40 (26.5) 18.60 0.523
  Vinorelbine- containing 40 (26.5) 48.16  
  Gemcitabine- containing 51 (33.8) 24.58  
  Paclitaxel- containing 20 (13.2) 24.41  
TopIIα Low expression 117 (77.5) 19.38 0.012*
  High expression 34 (22.5) NR  
Ki67 Low expression 96 (63.6) 22.24 0.517
  High expression 55 (36.4) 29.37  
  1. * P < 0.05 was considered statistically significant; # NR = not reached